There has been reported by clinical scientists that a macrocyclic lactone such as ivermectin showed some activity against new emerging SARS CoV-2 (COVID- 19). Since a biological mechanism proposed for this anti-viral effect is not solely adequate to draw a conclusion at the phycological scale, this in silico investigation is conducted to identify potential modes of action of ivermectin against COVID-19. In this regards, vast multi target molecular simulation is considered to assess not only Ivermectin, but also other structurally similar compounds to identify a possible therapeutical solution. Ivermectin and 14 other compounds, by which the infectivity and morbidity of the SARS CoV-2 may be limited.